Abstract
Objective:
To evaluate the effect of oral treosulfan in patients with platinum-resistant ovarian cancer.
Methods:
A phase II trial of oral treosulfan 500 mg per day in 30 females with platinum resistant ovarian cancer. All patients had measurable or evaluable disease.
Results:
The treatment was well tolerated. One patient (3%) achieved a partial response lasting 12+ months. Seven patients had stable disease for 5.3 months (median) range 4.4-7.5 months. Median time to progression was 11.5 weeks (95% C.L. 11-12 weeks). Median survival was 31 weeks (95% C.L. 30-35 weeks).
Conclusion:
Oral treosulfan in the present schedule is not recommended in platinum resistant ovarian cancer.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
-
Multicenter Study
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents / pharmacology*
-
Antineoplastic Agents, Alkylating / administration & dosage
-
Antineoplastic Agents, Alkylating / therapeutic use*
-
Busulfan / administration & dosage
-
Busulfan / analogs & derivatives*
-
Busulfan / therapeutic use
-
Carcinoma / drug therapy*
-
Cisplatin / pharmacology*
-
Denmark
-
Drug Administration Schedule
-
Drug Resistance, Neoplasm
-
Female
-
Humans
-
Middle Aged
-
Ovarian Neoplasms / drug therapy*
-
Quality of Life
-
Surveys and Questionnaires
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Antineoplastic Agents, Alkylating
-
treosulfan
-
Busulfan
-
Cisplatin